Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells

Date

2015-02-20

Author

LIMASALE, Yanuar Dwi Putra
Tezcaner, Ayşen
Özen, Can
Keskin, Dilek
Banerjee, Sreeparna

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

231
views

0
downloads

Cyclooxygenase-2 (COX-2) is highly expressed in many different cancers. Therefore, the inhibition of the COX-2 pathway by a selective COX-2 inhibitor, celecoxib (CLX), may be an alternative strategy for cancer prevention and therapy. Liposomal drug delivery systems can be used to increase the therapeutic efficacy of CLX while minimizing its side effects. Previous studies have reported the encapsulation of CLX within the non-targeted long circulating liposomes and functional effect of these formulations against colorectal cancer cell lines. However, the selectivity and internalization of CLX-loaded liposomes can further be improved by grafting targeting ligands on their surface. Cetuximab (anti-epidermal growth factor receptor - EGFR - monoclonal antibody) is a promising targeting ligand since EGFR is highly expressed in a wide range of solid tumors. The aim of this study was to develop EGFR-targeted immunoliposomes for enhancing the delivery of CLX to cancer cells and to evaluate the functional effects of these liposomes in cancer cell lines. EGFR-targeted ILs, having an average size of 120 nm, could encapsulate 40% of the CLX, while providing a sustained drug release profile. Cell association studies have also shown that the immunoliposome uptake was higher in EGFR-overexpressing cells compared to the non-targeted liposomes. In addition, the CLX-loaded-anti-EGFR immunoliposomes were significantly more toxic compared to the non-targeted ones in cancer cells with EGFR-overexpression but not in the cells with low EGFR expression, regardless of their COX-2 expression status. Thus, selective targeting of CLX with anti-EGFR immunoliposomes appears to be a promising strategy for therapy of tumors that overexpress EGFR.

Subject Keywords

Celecoxib, EGFR, Immunoliposomes, Cancer

URI

https://hdl.handle.net/11511/32504

Journal

INTERNATIONAL JOURNAL OF PHARMACEUTICS

DOI

https://doi.org/10.1016/j.ijpharm.2015.01.016

Collections

Graduate School of Natural and Applied Sciences, Article

Suggestions

OpenMETU
Core

Multiscale tumor modeling Ünsal, Serbülent; Acar, Aybar Can; Department of Health Informatics (2014) Cancer’s complex behavior decreases success rates of the cancer therapies. The usual steps cancer therapy are, deciding phase of the cancer and planing the therapy according to medical guidelines and there is no room or chance for personalized medicine. Simulation systems that use patient specific data as input and up-to-date scientific evidence as business rules has chance to help clinicians for evidence based personalized medicine practice.In this study our aim is creating a basic model to guide researche...
Modeling of Breast and Gynecological Cancers Data and Investigating New Biological Findings Ağyüz, Umut; Purutçuoğlu Gazi, Vilda (null; 2018-06-27) The breast and gynecological cancers are two most common fatal cancers’ types in women in the world [1]. In oncological literature, these two cancers types are typically worked together since they are the risk factors of each other if the patient has one of these diseases [2]. In general, the cancers, like the heart diseases, are the systems’ ilnesses in the sense that any malfunctions in the associated transaction pathways cause problems in the activation flow, resulting in tumors. Therefore, the mathemati...
Bioinformatic prediction and coexpression network identifies repurposed novel drugs for papillary thyroid cancer Temiz, Kubra (Orta Doğu Teknik Üniversitesi Enformatik Enstitüsü; 2022-10) Thyroid cancer is a type of cancer that affects the endocrine system and has a high malignancy. Papillary thyroid cancer, the most common subtype of thyroid cancer, also has well-differentiated features. Early diagnosed and well-differentiated thyroid cancer is generally associated with a good prognosis and/or survival rate. Therefore, it is of great importance to determine the molecular signatures of the disease. In this study, five papillary thyroid cancer-related gene expression datasets were analyzed us...
Microarray applications for determination of the effects of emodin on breast cancer cell lines Ekenel Qomi, Emilia; İşcan, Mesude; Çoruh, Nursen; Department of Biotechnology (2011) Cancer is a genetic disease that is characterized by uncontrolled cells growth. Breast cancer is a type of cancer originating from breast tissue. Some breast cancers are sensitive to hormones such as estrogen which makes it possible to treat them by blocking the effects of these hormones in the target tissues. These require less aggressive treatment than hormone negative cancers. Breast cancers without hormone receptors, are higher-risk, and are treated more aggressively. The aim of our study is to investig...
Investigaton of chemopreventive properties of Urtica Dioica L., in MCF-7 and MDA231 breast cancer cell lines Güler, Elif; İşcan, Mesude; Department of Biology (2011) Cancer is a major health problem in developing world with mostly unsufficient treatment. Cancer prevention through dietary modification appears to be a practical and cost effective possibility. The aim of present study is to investigate the chemical components of “Urtica diocia,L (U. diocia) grown in Turkey” and the possible protective potential of its aqueous extract against breast cancer cell lines. U. diocia was extracted by maceration method which was performed for 6,12, 24, and 36 hours, at 50°C, 37°C,...

Citation Formats

Y. D. P. LIMASALE, A. Tezcaner, C. Özen, D. Keskin, and S. Banerjee, “Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells,” INTERNATIONAL JOURNAL OF PHARMACEUTICS, pp. 364–373, 2015, Accessed: 00, 2020. [Online]. Available: https://hdl.handle.net/11511/32504.